中国全科医学2016，Vol.19Issue(27)：3265-3269,5.DOI:10.3969/j.issn.1007-9572.2016.27.002
瑞舒伐他汀对盐酸羟考酮缓释片治疗晚期非小细胞肺癌患者癌痛的增效作用和安全性研究
Synergy and Security Research of Rosuvastatin with Oxycodone Hydrochloride Controlled Release Tablets in Treating Advanced Non-small Cell Lung Cancer Patients' Cancer Pain
摘要
Abstract
Objective To investigate the synergy and security of rosuvastatin with oxycodone hydrochloride controlled release tablets in treating advanced non - small cell lung cancer patients' cancer pain. Methods From January 2014 to January 2015,we enrolled 160 patients with advanced non - small cell lung cancer who accorded with the inclusion criteria from the Oncology Department of Yishui Central Hospital of Linyi. These patients were assigned into treatment group and control group by random number table method,with 80 patients in each group. On the basis of conventional chemotherapy,control group was given oxycodone hydrochloride controlled release tablets,and treatment group was given oxycodone hydrochloride controlled release tablets plus rosuvastatin calcium tablets for analgesia. Before treatment and one week after treatment,the levels of IL-6 and TNF-α were detected. One week after treatment,the effective doses of the two groups were recorded;the times of breakthrough pain,NRS score and the effective rate of cancer pain treatment of the two groups were recorded when they were given the average effective dose of oxycodone hydrochloride controlled release tablets of the treatment group;the incidence rates of adverse reaction (constipation,nausea and vomiting,liver function damage and respiratory depression)of the two groups were recorded when the two groups were given effective doses of oxycodone hydrochloride controlled release tablets respectively. Results Before treatment,the two groups were not significantly different in the levels of IL-6 and TNF-α(P > 0. 05);after treatment,treatment group was lower than control group in the levels of IL-6 and TNF-α( P < 0. 05). Treatment group had lower IL-6 and TNF-αlevels after treatment than those before treatment(P < 0. 05). Treatment group was lower than control group in effective dosage, the times of breakthrough pain and NRS score(P < 0. 05). The effective rate of cancer pain treatment of treatment group was 97. 5%(78 / 80),higher than that of control group which was 80. 0%(64 / 80)(χ2 = 12. 269,P < 0. 01). Treatment group was lower than control group in the incidence of constipation(P < 0. 05);the two groups were not significantly different in the incidence rates of nausea and vomiting, liver function damage and respiratory depression ( P > 0. 05 ) . Conclusion Rosuvastatin plus oxycodone hydrochloride controlled release tablets has synergistic effect in the treatment of patients with advanced non - small cell lung cancer pain,and the incidence rates of adverse reactions can be lowered by reducing the dosage of oxycodone hydrochloride controlled release tablets.关键词
疼痛/癌,非小细胞肺/瑞舒伐他汀/盐酸羟考酮缓释片/增效作用/安全性Key words
Pain/Carcinoma,non - small - scell lung/Rosuvastatin/Oxycodone hydrochloride controlled release tablets/Synergistic effect/Safety分类
医药卫生引用本文复制引用
高艳丽,张宝奇..瑞舒伐他汀对盐酸羟考酮缓释片治疗晚期非小细胞肺癌患者癌痛的增效作用和安全性研究[J].中国全科医学,2016,19(27):3265-3269,5.基金项目
山东省医药卫生科技发展计划项目 （）
